Ardelyx Q3 Product Revenue $125.5M, Net Loss Narrows to $0.7M; Guidance Reiterated
ARDX is trading near its 52-week low of $2.955 (2.9% above the low).
Summary
Ardelyx grew Q3 product revenue 19% to $125.5M and narrowed its net loss to $0.7M, while reiterating full-year 2026 guidance and finishing enrollment early in its Phase 3 CIC trial.
Key Events · Earnings and Guidance · ARDX
-
Q3 Product Revenue Grows 19%
Total product revenue was $125.5M versus $105.5M a year earlier, with IBSRELA at $96.3M (+23%) and XPHOZAH at $29.2M (+7%).
-
Net Loss Narrows to $0.7M
Net loss fell to $0.7M, or $(0.00) per share, from $1.0M a year ago, helped by a gross margin above 95% and $15.1M of share-based compensation.
-
Full-Year Guidance Reiterated
Management kept IBSRELA at $350-$370M, XPHOZAH at $110-$120M and operating expenses below $500M, and maintained the $1B long-term IBSRELA target.
-
ACCEL Phase 3 Fully Enrolled
The ~700-patient CIC trial completed enrollment ahead of schedule, with topline data expected in the second half of 2027.
Analysis · ARDX · Life Sciences
The commercial engine is working: total product revenue of $125.5M grew 19% year-over-year, led by IBSRELA at $96.3M (+23%), and the net loss shrank to $0.7M from $1.0M a year ago. Just as important, management reiterated rather than cut full-year guidance — IBSRELA $350-$370M, XPHOZAH $110-$120M, operating expenses below $500M — after the prior quarter's $60M IBSRELA guidance reduction, which is the key reason the stock sits near its 52-week low. The balance sheet carries $285.3M in cash and investments, and the Phase 3 ACCEL trial in chronic idiopathic constipation is fully enrolled ahead of schedule with topline data expected in the second half of 2027. A new U.S. patent issuing November 10, 2026 extends formulation protection on both products to December 2041. The open question is whether the reiterated numbers are conservative enough to survive payor friction on IBSRELA; the next hard checkpoint is the Q4 report and the 2027 ACCEL readout.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARDX was trading at $3.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $755M. The 52-week trading range was $2.96 to $8.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.